Fludarabine
Recurrent or Metastatic Solid Tumors With Positive ALPP
Haifeng QinSmall moleculeEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Recurrent or Metastatic Solid Tumors With Positive ALPP cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Haifeng Qin | Early Phase 1 | C |
Anti Alpp Car-T Cells Treatment Haifeng Qin | Early Phase 1 | C |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →